Market News AIOpen the app

GeoVax Labs lost $4.2 million last quarter and stopped working on its COVID-19 vaccine.

ResultsRead the original at moomoo.com
Bad for GOVX

GeoVax's loss narrowed, but it had no revenue and expects its cash and loan to fund operations only into December 2026. That funding risk outweighs lower research costs; the company also stopped GEO-CM04S1 and GEO-MVA manufacturing costs rose.

GOVX · GeoVax Labs

AI read · Bad for GOVX

The AI's read

The smaller loss offers some relief. But lower research spending partly followed the end of a federal contract and cuts to two programs, while manufacturing costs rose for GEO-MVA. With no sales and funding expected to last only into December, continued operations are the central concern.

Get alerts for GOVX

Follow GeoVax Labs (GOVX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GOVX
Free on the App Store and Google Play, or on the web.